A Novel Insight Into CRPC Progression and Immune: Evidence From Single-cell Spatial Transcriptome Multi-omics

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Eligibility Criteria

Inclusion Criteria: 1. Male patients, age \>18 and \<85 years. 2. Histologically confirmed prostate adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma. 3. Evidence of distant metastases by imaging (according to RECIST criteria). 4. No prior systemic therapy for prostate cancer (no ADT or other systemic treatments). 5. ECOG performance status 0-2 and estimated life expectancy \>6 months. 6. Adequate organ function as indicated by: * Hemoglobin ≥ 90 g/L * ANC ≥ 1.5 × 10\^9/L * Platelet count ≥ 75 × 10\^9/L * WBC ≥ 3 × 10\^9/L ⑤ Total bilirubin ≤ ULN ⑥ ALT/AST ≤ 2.5 × ULN ⑦ Creatinine clearance ≥ 30 mL/min (Cockcroft-Gault formula) * INR ≤ 1.5 or PT \< 4 sec above ULN 7. Ability to provide written informed consent. Exclusion Criteria: 1. Histological diagnosis of neuroendocrine or small-cell prostate cancer. 2. No evidence of distant metastases on imaging. 3. Prior systemic therapy for prostate cancer (neoadjuvant, adjuvant, or syste…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source